New hope for young heart patients: less invasive valve replacement under study

NCT ID NCT06830499

Recruiting now Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how safe and effective a less invasive heart valve replacement (called Sapien 3 TAVR) is for younger patients (ages 50-70) in China with severe aortic stenosis. Researchers will track 450 participants for up to 5 years to see survival rates and complications. The goal is to see if this procedure works well long-term in this younger group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aortic Valve Disease aortic valve disease 1 aortic valve disease 2 aortic valve disorder aortic valve stenosis Bicuspid Aortic Valve Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE DISEASES BICUSPID AORTIC VALVE (BAV)

Contacts and locations

Locations

Department of Cardiovascular Surgery of Xijing Hospital, Air Force Military Medical University
RECRUITING

Xi'an, Shaanxi, 710032, China
Fuwai Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITING

Beijing, China
Shanghai Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, China
West China Hospital, Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.